Apyx Medical CorporationAPYXNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
-0.8%/yr
vs +45.5%/yr prior
Acceleration
-46.3pp
Decelerating
Percentile
P85
Within normal range
vs 3Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.85% |
| Q3 2025 | -2.79% |
| Q2 2025 | 2.49% |
| Q1 2025 | -28.02% |
| Q4 2024 | -2.19% |
| Q3 2024 | -19.80% |
| Q2 2024 | 1.93% |
| Q1 2024 | 11.94% |
| Q4 2023 | -11.43% |
| Q3 2023 | 3.83% |
| Q2 2023 | 6.77% |
| Q1 2023 | 1.27% |
| Q4 2022 | 18.28% |
| Q3 2022 | -0.84% |
| Q2 2022 | -7.60% |
| Q1 2022 | 22.28% |
| Q4 2021 | -19.40% |
| Q3 2021 | 8.39% |
| Q2 2021 | -2.78% |
| Q1 2021 | 21.46% |
| Q4 2020 | -12.32% |
| Q3 2020 | 7.38% |
| Q2 2020 | -0.51% |
| Q1 2020 | -10.67% |
| Q4 2019 | 17.20% |
| Q3 2019 | 5.41% |
| Q2 2019 | 9.63% |
| Q1 2019 | 39.90% |
| Q4 2018 | -5.55% |
| Q3 2018 | -24.88% |
| Q2 2018 | 45.20% |
| Q1 2018 | 27.73% |
| Q4 2017 | -27.87% |
| Q3 2017 | -12.36% |
| Q2 2017 | -1.83% |
| Q1 2017 | 4.88% |
| Q4 2016 | -0.88% |
| Q3 2016 | 15.20% |
| Q2 2016 | -11.38% |
| Q1 2016 | 6.71% |